A Study of Eloralintide (LY3841136) in Participants With Overweight or Obesity

ConditionsOverweight Obesity

Trial statusNot yet recruiting

Trial phasePhase 1

Trial typeInterventional

Biological sexAll

Age18-70

SponsorEli Lilly and Company

About this trial

The main purpose of the study is to measure and compare the effects of eloralintide and placebo on insulin sensitivity (how your body responds to insulin), metabolic health (things like sugar and cholesterol), and body weight in participants with obesity or overweight. For each participant, the study will last about 35 weeks and include 3 in patient visits totaling 7 days.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Have an hemoglobin A1c (HbA1c) value at screening of less than 6.5 percent (%).

Have a body mass index between 25 and 45 Kilogram per Square Meter (kg/m²).

Have had a stable body weight that has changed by less than 5% during the 3 months prior to screening.

Are individuals assigned male at birth (AMAB) or assigned female at birth (AFAB). Individuals of childbearing potential (IOCBP) and individuals not of childbearing potential (INOCBP) may participate in this study.

Disqualifiers

Have type 1 or type 2 diabetes mellitus, a history of ketoacidosis, or of hyperosmolar state or coma. Note: Participants with a history of gestational diabetes are eligible to participate in this study.

Have acute or chronic pancreatitis or a history of acute idiopathic pancreatitis.

Have a known clinically significant gastric emptying abnormality or chronically take drugs that directly affect gastrointestinal (GI) motility to a significant extent.

liposuction

Trial design

Design model

Parallel

Treatments tested in this trial

Eloralintide
Drug
Eloralintide administered SC
Placebo
Other intervention
Placebo administered SC

Treatment groups

115 Participants

are divided into 2 treatment groups

Group A: EloralintideExperimental treatment 1 intervention

Group B: PlaceboPlacebo comparator 1 intervention

Trial outcomes

Primary outcomes

Change From Baseline In Hyperinsulinemic Euglycemic Clamp (HEC) Predicted Clamp-Derived Insulin Sensitivity (M-value)

Time frame

Baseline, Week 24

Secondary outcomes

Change From Baseline In Body Weight

Time frame

Baseline, Week 24

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Eli Lilly and Company

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: